Molecular Evidence of Coinfection with Acute Respiratory Viruses and High Prevalence of SARS-CoV-2 among Patients Presenting Flu-Like Illness in Bukavu City, Democratic Republic of Congo

Table 3

Logistic regression analysis regarding demographical gender, exposition, and comorbidity between positive influenza A and B patients.

	INFL A		INFL. A		INFL B		INFL. B
	Neg. (N = 1276)	Pos. (N = 76)	OR (IC)		Neg. (N = 1340)	Pos. (N = 12)	OR (IC)
Symptoms (%)
Fever	48.2	58.3	1.51 (0.46–4.98)	0.558	49.0	51.2	1.04 (0.21, 5.22)	1.000
Coldness feeling	53.3	16.7	0.18 (0.04–0.83)	0.017	50.3	51.5	0.99 (0.20, 4.94)	1.000
Shivering	40.1	25.0	0.50 (0.13–1.92)	0.369	38.8	51.5	1.58 (0.32, 7.91)	0.682
Sweating	24.8	25.0	1.01 (0.26–3.95)	1.000	25.2	0.0	—	—
Cough	77.4	58.3	0.41 (0.12–1.38)	0.163	76.2	51.3	0.31 (0.06, 1.57)	0.155
Breathing difficulties	22.6	25.0	1.14 (0.29–4.47)	1.000	22.4	51.2	3.45 (0.69, 17.38)	0.135
Essoufflés	16.1	25.0	1.74 (0.44–6.95)	0.425	17.0	0.0	—	—
Headaches	71.5	66.7	0.80 (0.23–2.80)	0.745	70.7	100.0	—	—
Asthenia	59.1	50.0	0.69 (0.21–2.25)	0.556	58.5	51.5	0.71 (0.14, 3.55)	0.697
Myalgia	48.9	25.0	0.35 (0.09–1.34)	0.139	46.9	51.5	1.13 (0.23, 5.66)	1.000
Anorexia	31.4	25.0	0.73 (0.19–2.83)	0.755	30.6	51.5	2.27 (0.45, 11.37)	0.379
Sputum	25.5	8.3	0.26 (0.03–2.13)	0.295	23.8	51.1	3.20 (0.64, 16.09)	0.155
Dyspnea	16.1	25.0	1.74 (0.44–6.95)	0.425	17.0	0.0	—	—
Expositions (%)
Stay in high risk areas	14.6	16.7	1.17 (0.24–5.74)	0.692	15.0	0.0	—	—
Close contact	4.4	0.0	—	—	4.1	0.0	—	—
Work in hospitals	5.1	0.0	—	—	4.8	0.0	—	—
Comorbidities (%)
Immunosuppression	0.7	0.0	—	—	0.7	0.0	—	—
Hypertension	9.5	16.7	1.91 (0.38–9.66)	0.346	10.2	0.0	—	—
Obesity	2.2	8.3	4.06 (0.39–42.37)	0.288	2.7	0.0	—	—
Diabetes	7.3	16.7	2.54 (0.49–13.21)	0.249	8.2	0.0	—	—
Chronic resp. Dis.	3.6	0.0	—	—	3.4	0.0	—	—
Chronic cardiac dis.	0.0	0.0	—	—	0.0	0.0	—	—
Chronic kidney dis.	0.7	0.0	—	—	0.7	0.0	—	—
Chronic liver dis.	0.0	0.0	—	—	0.0	0.0	—	—
Chronic neurologic dis.	0.7	0.0	—	—	0.7	0.0	—	—

Very significant.